APA (7th ed.) Citation

C, C., X, N., H, L., R, Z., L, G., W, L., . . . D, L. (2025). Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants. Clinical drug investigation, 45(4), 179. https://doi.org/10.1007/s40261-025-01428-9

Chicago Style (17th ed.) Citation

C, Cui, Niu X, Li H, Zhang R, Geng L, Lin W, Liu Z, Wang X, and Liu D. "Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants." Clinical Drug Investigation 45, no. 4 (2025): 179. https://doi.org/10.1007/s40261-025-01428-9.

MLA (9th ed.) Citation

C, Cui, et al. "Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants." Clinical Drug Investigation, vol. 45, no. 4, 2025, p. 179, https://doi.org/10.1007/s40261-025-01428-9.